Clinical trial · Interventional
Evaluation of Brain Metastases Treated With Stereotactic Radiotherapy Using Dynamic [18F]FDG PET
NCT06511323CI-TRIAL-00078963not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the clinical usefulness of dynamic \[18F\]FDG PET imaging in assessing brain metastasis post stereotactic radiotherapy to separate true progression from the treatment-related changes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Observational
- description
- This is a prospective, single-arm, pilot diagnostic study to evaluate the diagnostic accuracy of using dynamic \[18F\]FDG PET in 70 patients with brain metastases managed with stereotactic radiosurgery(SRS)/fractionated stereotactic radiotherapy (FSRT). The study will include imaging assessments at baseline, at 10 weeks after treatment, and at first concern for progression or 12 months post-treatment, whichever comes earlier.
- interventionNames
- Diagnostic Test: dynamic [18-FDG PET] scan post stereotactic radiation for brain metastases
Primary outcomes (1)
- measure
- Diagnostic accuracy of dynamic PET
- timeFrame
- 12-month follow-up.
- description
- Diagnostic accuracy will be calculated and compared based on the index lesion.
Secondary outcomes (9)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 or older. * Willing and able to provide consent. * ECOG 0-2. * Life expectancy ≥12 months. * Creatinine clearance ≥30 ml/min within 28 days prior to registration. * At the discretion of the treating oncologist, it is believed that at least 1 lesion (or resection cavity) is best managed with SRS/SFR Exclusion Criteria: * Pregnant or nursing women. * Men or women of childbearing potential who are unwilling to employ adequate contraception. * Inability to complete a brain MRI. * Known allergy to gadolinium. * Inability to complete a PET scan. * Uncontrolled diabetes mellitus. * Primary germ cell tumour, primary CNS tumour, or lymphoma * SRS/FSRT is no longer indicated for any BMs * Must be able to read and write English
References
Publications (0)
Data not yet available
No reference posted for this study.